CYTOGAM cytomegalovirus immune globulin intravenous (human) Updated Jul 13
CYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.
- Sole FDA-approved CMV hyperimmune globulin for transplant, no direct approved competitor in the US market, giving Kamada an effective monopoly in this niche
- Revenue growing strongly: CYTOGAM sales reached $22.5M in 2024, up 31% YoY (per Kamada's 2024 annual results)
- Kamada received FDA approval to manufacture CYTOGAM in-house (May 2023), improving vertical integration and margins at the Beit Kama facility
- Small contributor to Kamada's overall business: CYTOGAM's ~$22.5M is only ~12-13% of total 2024 revenue of $180.5M, making it a minority driver of the stock
- No near-term binary catalyst, SHIELD study primary completion is December 2027, no upcoming PDUFA or pivotal readout within 12 months
- Competition from standard-of-care oral antivirals (valganciclovir/ganciclovir) is well-established, and CYTOGAM is an adjunctive add-on, not a standalone replacement